Get the Stockscreener App
0.8398
2.02%
0.0166
After Hours:
.84
0.0002
+0.02%
Atossa Therapeutics Inc stock is traded at $0.8398, with a volume of 491.90K.
It is up +2.02% in the last 24 hours and up +8.67% over the past month.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.
See More
Previous Close:
$0.8232
Open:
$0.8286
24h Volume:
491.90K
Relative Volume:
0.46
Market Cap:
$108.48M
Revenue:
-
Net Income/Loss:
$-26.91M
P/E Ratio:
-3.8173
EPS:
-0.22
Net Cash Flow:
$-19.57M
1W Performance:
+6.57%
1M Performance:
+8.67%
6M Performance:
+17.18%
1Y Performance:
-44.01%
1-Day Range:
$0.827
$0.8469
1-Week Range:
$0.78
$0.8469
52-Week Range:
$0.5526
$1.66
Atossa Therapeutics Inc Stock (ATOS) Company Profile
Name
Atossa Therapeutics Inc
Sector
Industry
Phone
206.588.0256
Address
10202 5TH AVENUE NE, SEATTLE, WA
Compare ATOS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ATOS
Atossa Therapeutics Inc
|
0.8398 | 103.13M | 0 | -26.91M | -19.57M | -0.22 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Atossa Therapeutics Inc Stock (ATOS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-26-18 | Initiated | Maxim Group | Buy |
Atossa Therapeutics Inc Stock (ATOS) Latest News
Will Atossa Therapeutics Inc. stock recover after recent dropJuly 2025 Earnings & Daily Risk Controlled Trade Plans - Newser
Real time breakdown of Atossa Therapeutics Inc. stock performanceTreasury Yields & Stepwise Trade Signal Guides - Newser
Full technical analysis of Atossa Therapeutics Inc. stock2025 Trade Ideas & Weekly Hot Stock Watchlists - Newser
Atossa Therapeutics Inc.’s volatility index tracking explainedBear Alert & Fast Moving Stock Trade Plans - Newser
How to build a dashboard for Atossa Therapeutics Inc. stockWatch List & Fast Entry Momentum Alerts - Newser
Will Atossa Therapeutics Inc. stock go up soon2025 Bull vs Bear & Daily Volume Surge Signals - Newser
What to expect from Atossa Therapeutics Inc. in the next 30 daysRecession Risk & Safe Entry Point Identification - Newser
Can technical indicators confirm Atossa Therapeutics Inc.’s reversalJuly 2025 Sentiment & Expert Verified Movement Alerts - Newser
Ranking Atossa Therapeutics Inc. among high performing stocks via toolsWeekly Stock Recap & Free Expert Verified Stock Movement Alerts - Newser
NioCorp and Atossa Therapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - Livingston Daily
What recovery options are there for Atossa Therapeutics Inc.Stop Loss & Fast Gain Stock Trading Tips - Newser
Custom watchlist performance reports with Atossa Therapeutics Inc.2025 Technical Overview & Low Drawdown Trading Strategies - Newser
Key metrics from Atossa Therapeutics Inc.’s quarterly dataGap Down & Verified Momentum Stock Watchlist - Newser
Analyzing drawdowns of Atossa Therapeutics Inc. with statistical tools2025 Momentum Check & Expert Verified Movement Alerts - Newser
Leading vs lagging indicators on Atossa Therapeutics Inc. performance2025 Earnings Surprises & Technical Buy Zone Confirmations - Newser
Using economic indicators to assess Atossa Therapeutics Inc. potential2025 Short Interest & Verified Technical Signals - Newser
Atossa Therapeutics Receives Nasdaq Non-Compliance Notice - MSN
How to escape a deep drawdown in Atossa Therapeutics Inc.Forecast Cut & Daily Entry Point Trade Alerts - Newser
Has Atossa Therapeutics Inc. found a price floorJuly 2025 Review & Long Hold Capital Preservation Plans - Newser
analyzing drawdowns of atossa therapeutics inc. with statistical toolsOptions Play & Low Drawdown Investment Ideas - Newser
Using data models to predict Atossa Therapeutics Inc. stock movementJuly 2025 Catalysts & Daily Risk Controlled Trade Plans - Newser
What does recent volatility data suggest for Atossa Therapeutics Inc.July 2025 Levels & Safe Capital Investment Plans - Newser
H.C. Wainwright Maintains Atossa Therapeutics(ATOS.US) With Buy Rating, Maintains Target Price $7 - 富途牛牛
Atossa Genetics stock rating reiterated by H.C. Wainwright on FDA meeting plans - Investing.com Australia
Institutional scanner results for Atossa Therapeutics Inc.2025 Buyback Activity & Expert Approved Trade Ideas - Newser
Atossa at H.C. Wainwright: Zinhoxifen’s Dual Pathway Strategy By Investing.com - Investing.com Canada
Atossa Therapeutics Inc. Shows Early Signs of Technical StrengthJuly 2025 Final Week & Free Low Drawdown Momentum Trade Ideas - beatles.ru
Atossa Therapeutics Inc Stock (ATOS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):